Clinical Trial

The Effect of AMG 133 on Gastric Emptying

Completed Phase 1
View on ClinicalTrials.gov →
Summary
The primary objective of the trial is to evaluate the effect of AMG 133 versus placebo on acetaminophen pharmacokinetics (PK), a marker for gastric emptying, in participants living with overweight or obesity.
Trial Details
NCT Number NCT07429032
Lead Sponsor Amgen
Conditions Overweight or Obesity
Enrollment 57 participants
Start Date 2025-04-17
Primary Completion 2025-11-26 (estimated)
Study Completion 2025-11-26 (estimated)
Updated on ClinicalTrials.gov 2026-02-24